Other Funding Sources

We recognize the financial burdens that some patients and their families may experience in gaining access to our medicines. We are committed to assisting all eligible patients obtain access to our medicines, regardless of their ability to pay.

If you have no insurance, or you are effectively uninsured because your health insurance plan denies you access to XOLAIR^® (Omalizumab) for Subcutaneous Use, you can apply to the Genentech^® Access to Care Foundation for help with your treatment.

For additional information and potential resources, you may want to visit the following websites:

Access to Benefits Coalition: The Access to Benefits Coalition (www.accesstobenefits.org) is a national program available in 37 states with local offices which provides counseling to Medicare beneficiaries who need financial assistance.
Appeal Solutions: Appeal Solutions (www.appealsolutions.com) is a leading provider of services focusing entirely on the resolution of denied or disputed medical insurance claims.
Centers for Medicare & Medicaid Services (CMS): The Centers for Medicare & Medicaid Services (www.cms.hhs.gov) is a federal agency within the U.S. Department of Health & Human Services. CMS runs the Medicare and Medicaid programs, two national health care programs that benefit about 75 million Americans.
COBRA Insurance: Consolidated Omnibus Budget Reconciliation Act insurance (www.cobrainsurance.net) can provide short-term insurance coverage.
HealthInsuranceInfo.net: HealthInsuranceInfo.net (www.healthinsuranceinfo.net) is a consumer guide for getting and keeping health insurance.
NeedyMeds: NeedyMeds (www.needymeds.com) is a place to learn about patient assistance programs and other programs designed to help those who can't afford their medicines. NeedyMeds is not a program but an information resource.
State Health Insurance Assistance Programs: The State Health Insurance Assistance Program (www.shiptalk.org) is a national CMS-funded program with state offices that counsels the Medicare population on their health insurance.

XOLAIR (Omalizumab) for Subcutaneous Use Indication

XOLAIR is indicated for adults and adolescents (12 years of age and older) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with ICS. XOLAIR has been shown to decrease the incidence of asthma exacerbations in these patients. Safety and efficacy have not been established in other allergic conditions.

WARNING

Anaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, patients should be closely observed for an appropriate period of time after XOLAIR administration, and health care providers administering XOLAIR should be prepared to manage anaphylaxis that can be life-threatening. Patients should also be informed of the signs and symptoms of anaphylaxis and instructed to seek immediate medical care should symptoms occur (see WARNINGS, and PRECAUTIONS, Information for Patients).

XOLAIR Safety Information

XOLAIR should only be administered in a health care setting by health care providers prepared to manage anaphylaxis that can be life- threatening.
XOLAIR should not be administered to patients who have experienced a severe hypersensitivity reaction to XOLAIR (see Boxed WARNING). XOLAIR should be discontinued in patients who experience a severe hypersensitivity reaction.
Malignant neoplasms were observed in 20 of 4127 (0.5%) XOLAIR- treated patients compared with 5 of 2236 (0.2%) control patients in clinical studies of asthma and other allergic disorders.
Patients should be given and instructed to read the Medication Guide before starting treatment and before each subsequent treatment.
Patients receiving XOLAIR should be told not to decrease the dose of, or stop taking any other asthma medications unless otherwise instructed by their physician.
The adverse reactions most commonly observed among patients treated with XOLAIR in clinical studies included injection site reaction (45%), viral infections (23%), upper respiratory tract infection (20%), sinusitis (16%), headache (15%), and pharyngitis (11%). These events were observed at similar rates in XOLAIR-treated patients and control patients.

Please see full Prescribing Information, including Boxed WARNING and Medication Guide, for additional Important Safety Information.

Please note: This website contains links to a number of other sites that may offer useful information. We suggest visiting those sites directly to obtain information on specific details of coverage, educational and financial support services for XOLAIR® (Omalizumab). Genentech, Inc. and Novartis Pharmaceuticals Corporation are not partners with or affiliated with any company listed. The availability of health insurance coverage and financial assistance varies from company to company, plan to plan and state to state. Genentech, Inc. and Novartis Pharmaceuticals Corporation do not imply or guarantee that a specific health insurance plan or any other company will provide coverage or assistance for XOLAIR. Genentech, Inc. and Novartis Pharmaceuticals Corporation are not responsible for any decisions regarding partial or non-coverage of XOLAIR.